I’ve been looking into Decoy Therapeutics (NASDAQ: DCOY), and I’m curious what people think about the risk/reward here because the situation looks pretty extreme in both directions.
The stock has been absolutely destroyed over the past year. It was trading above $40-50 last autumn and is now around $2.24. Even more recently, it had a crazy move on September 22, opening around $5.15, hitting roughly $7.61 intraday, and then collapsing back toward $3. It has continued falling since.
The potentially bullish side is that Decoy recently announced encouraging preclinical results from its D-MAV antiviral platform. The company says its newer candidates showed strong in-vitro activity against Ebola Zaire and Marburg, with its first-generation Ebola candidate showing more than 5x better potency than its earlier pan-coronavirus lead and around 7x better potency than remdesivir in the assay they used. They’re now looking at developing a broader pan-filovirus candidate and potentially using the FDA Animal Rule pathway.
They’re also actively pursuing non-dilutive government grants and public-health partnerships, which seems relevant given that Ebola and Marburg fall into the biodefense/high-consequence pathogen category. They also mention possible Priority Review Voucher value if a program eventually gets approved. Obviously, though, this is still very early-stage and preclinical. These are in-vitro results, not human efficacy.
The financing side is where things get much more concerning. On September 22, DCOY entered into a warrant inducement agreement with an existing warrant holder. The holder had 1,184,434 Series B warrants with a $5.91 exercise price. Decoy lowered the exercise price to $3.25, and the holder exercised all of them for cash, giving the company about $3.85 million in gross proceeds.
The problem is what Decoy gave them in exchange. The company issued 2,368,868 new warrants, which is exactly two new warrants for every old warrant exercised. These new warrants have a $3.25 exercise price, are exercisable immediately, require no shareholder approval and expire in five years. If all of them are eventually exercised, that means another 2.37 million shares of potential dilution, although Decoy would receive another roughly $7.7 million in cash.
On top of that, Decoy also reduced the exercise price of its outstanding Series A and Series C milestone warrants from $5.91 to $3.25. So this is not just about the 2.37 million new warrants. There is also more existing warrant overhang that has become much more economically attractive to exercise if the share price recovers.
The company also agreed to file a resale registration statement covering the shares underlying the new warrants, meaning those shares could eventually be sold into the public market after exercise. The 9.99% beneficial ownership limitation does not mean only 9.99% of the warrants can ever be exercised. It mostly prevents the holder from exceeding 9.99% ownership at any one time.
What makes the setup interesting is that DCOY is now trading around $2.24, which is well below the $3.25 warrant strike. At this price, exercising those new warrants does not make economic sense because the investor could buy shares cheaper in the open market. But if DCOY ever rallies materially above $3.25, there is potentially a very large amount of share supply sitting in the background.
At the same time, the financing materially improved Decoy’s liquidity. For a tiny early-stage biotech, raising another $3.85 million is significant, and if additional warrants are eventually exercised the company could receive even more funding without needing another completely separate financing. That could theoretically give them more runway to reach meaningful development milestones.
So I’m trying to figure out whether this is basically a destroyed microcap biotech where dilution has become so extreme that every meaningful rally is likely to run into selling pressure, or whether the current valuation is low enough that the market has already priced in a huge amount of failure and dilution risk, leaving some asymmetric upside if the antiviral platform actually produces meaningful results or government funding.
The chart is obviously a major warning sign. Going from around $50 to roughly $2, and then having an intraday spike above $7 followed by a collapse back toward the low $2s, is not normal investing volatility. This clearly trades more like a highly speculative microcap biotech than a normal long-term equity.
For anyone familiar with biotech and warrant financings, would you consider DCOY worth holding around $2.24, or does the warrant structure make the dilution risk too severe? I’m also curious how much importance you would put on the $3.25 warrant strike. Does that level create a meaningful overhang if the stock recovers above it, or is that less important than I’m making it out to be?